Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06258213 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral ABP-745 Administration in Healthy Volunteers
A Phase 1 study, sponsored by Atom Therapeutics Co..
- Completed
- Registry status
- Phase 1
- Development phase
- 90
- Enrollment target
NCT06258213 is a Phase 1 study that has completed, run by Atom Therapeutics Co.. The registered enrollment target is 90 participants.
The verdict
NCT06258213, a Phase 1 study, has completed, sponsored by Atom Therapeutics Co..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 90 participants
- Enrollment target
Study Summary
A randomized, double-blind, placebo-controlled, dose-escalation study will be conducted in healthy volunteers. This study will evaluate the safety, tolerability, and pharmacokinetics (PK) of ABP-745 following single (Part 1) and multiple (Part 2) oral doses.
Interventions
- DRUG Placebo
- DRUG ABP-745
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2024-01-23 |
| Est. Completion | 2024-07-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06258213
The ClinicalTrials.gov registry entry for NCT06258213 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Atom Therapeutics Co., which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06258213 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06258213 about?
NCT06258213 is a clinical study titled "A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral ABP-745 Administration in Healthy Volunteers". A randomized, double-blind, placebo-controlled, dose-escalation study will be conducted in healthy volunteers. This study will evaluate the safety, tolerability, and pharmacokinetics (PK) of ABP-745 following single (Part 1) and multiple (Part 2) oral doses.
What is the current status of trial NCT06258213?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 90 participants. The study started on 2024-01-23. Estimated completion is 2024-07-29.
What interventions are being tested in trial NCT06258213?
The interventions under investigation include: Placebo (DRUG), ABP-745 (DRUG).
Who is sponsoring clinical trial NCT06258213?
This trial is sponsored by Atom Therapeutics Co., which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.